耐受性
慢性炎症性脱髓鞘性多发性神经病
医学
多发性神经病
内科学
重症监护医学
免疫学
不利影响
抗体
作者
Jeffrey A. Allen,Ivana Basta,Christian Eggers,Jeffrey T. Guptill,Kelly Gwathmey,Channa Hewamadduma,Remy Loris,Yessar Hussain,Satoshi Kuwabara,Frank Leypoldt,Jie Lin,Marta Lipowska,Mark J. Lowe,Giuseppe Lauria,Luís Querol,Niraja Suresh,Anissa Tse,Peter Ulrichts,P. van Doorn,Benjamin Van Hoorick,Ryo Yamasaki,Richard A. Lewis
出处
期刊:Neurology
[Ovid Technologies (Wolters Kluwer)]
日期:2024-04-09
卷期号:102 (17_supplement_1)
标识
DOI:10.1212/wnl-.0000000000206324
摘要
Assess the efficacy and safety of subcutaneous (SC) efgartigimod PH20 (co-formulated with recombinant human hyaluronidase PH20) in chronic inflammatory demyelinating polyneuropathy (CIDP).
科研通智能强力驱动
Strongly Powered by AbleSci AI